Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  plerixafor
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-23 of 23 for your search:
Start Over
Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
Phase: Phase III
Type: Treatment
Status: Active
Age: 10 to 75
Sponsor: NIAID
Protocol IDs: 140185, 14-I-0185, NCT02231879
Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-273, NCT00903968
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: PLERIFLAG, NCT01435343
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120003, 12-C-0003, NCT01468311
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: BRN0023, NCI-2013-02012, P30CA124435, NCT01977677
Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 to 30
Sponsor: Pharmaceutical / Industry
Protocol IDs: SC001, NCT01403896
Collection of Transplant Stem Cells for Plasma Cell Myeloma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI
Protocol IDs: 120074, 12-C-0074, NCT01547806
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201403068, NCT02098109
A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX301-03, NCT02200380
Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: ACT13710, U1111-1152-4403, NCT02221479
Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: ACT12781, U1111-1152-4309, NCT02221492
Gene Therapy for Fanconi Anemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 2097.00, NCI-2011-00202, P30CA015704, NCT01331018
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 10-329, MAMO0909-6, NCT01339039
Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 1104011617, NCT01352650
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Primal study, NCT01455025
Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor, NCT01610999
To Assess the Safety of Continuous IV Administration of Plerixafor (Mozobil) in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 16 and over
Sponsor: Other
Protocol IDs: CAM-PLEX, 2014-000117-31, NCT02179970
HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 to 66
Sponsor: NCI, Other
Protocol IDs: 2673.00, NCI-2014-02395, 2673, P30CA015704, R01HL116217, NCT02343666
Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Phase: No phase specified
Type: Supportive care
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: GCO # 09-0824, NCT01042717
Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC)
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PHANTASTIC, 2009-013798-16, NCT01186224
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 78
Sponsor: NCI, Other
Protocol IDs: CASE2410, NCI-2011-01281, P30CA043703, NCT01408043
Start Over